Small Pharma Engages Market-Maker

LONDON, May 07, 2021 unless the Company provides written notice of termination to GIACP at least 30 days prior to the end of the Term or GIACP provides a written notice of termination to the Company.

GIACP will be responsible for the costs it incurs in buying and selling the Shares, and no third party will be providing funds or securities for the market making activities.

Small Pharma is a neuropharmaceutical company specialised in IP led development of novel treatments for mental health conditions, with a focus on depression.

Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

Any references to quality, consistency, efficacy and safety of potential therapies do not imply that Small Pharma verified such in clinical trials or that Small Pharma will complete such trials.

Small Pharma’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended or any state securities laws and may not be offered or sold within the United States or to U.S.

…Read the full story